DRMA Dermata Therapeutics, Inc.
Company Updates ·
Dermata Therapeutics enrolled the first participant in a clinical trial of Tome Clearing Treatment, its once-weekly acne treatment. The company expects to launch its second commercial product in the first half of 2027.
Dermata Therapeutics agreed to sell 2,293,608 shares, or pre-funded warrants, at $1.46 per share, with Series E and Series F warrants attached. Gross proceeds are expected to be about $3.4 million before offering expenses.
Dermata Therapeutics reported $4.4 million in cash and cash equivalents at June 30, 2026, and said it expects to launch Tome Foundational Treatment on August 25, 2026. Cash is expected to fund operations into the fourth quarter of 2026.
Dermata Therapeutics expects its first commercial product, Tome Foundational Treatment, to be available for sale starting August 25, 2026. The set of four once-weekly treatments sells for $178, about $45 per treatment.
At its May 27, 2026 annual meeting, Dermata Therapeutics shareholders approved raising the share reserve of its 2021 equity plan to 402,214 shares and repricing warrants for up to 120,734 shares. Three Class II directors were elected.
Dermata Therapeutics said its at-the-market facility produced $2.0 million of net proceeds in the first quarter of 2026. Cash was $6.9 million at March 31, 2026, and the company expects its resources to fund operations into the first quarter of 2027.
Nasdaq staff told Dermata on August 22, 2025 that the company again meets the $1.00 minimum bid price, which closes the matter. The company needed a hearing panel's exception to reach that point, and its 8-K gives no cash figure.
Dermata said on May 16, 2025 that Nasdaq's staff has confirmed it regained compliance with the stockholders' equity requirement, but a bid price notice says its securities will be suspended on May 23, 2025 unless it requests a hearing by May 21. The company plans to request one.
Dermata agreed with holders of warrants for 4,834,470 shares to exercise at a reduced $1.284 a share, for about $6.2 million before fees. In return they receive new Series A and Series B warrants for up to 4,980,806 and 4,688,134 shares.
Dermata reported stockholders' equity of about $1.6 million against the $2.5 million Nasdaq minimum. It must regain compliance or submit a plan by May 9, 2025.
Dermata Therapeutics, Inc. describes itself as a scientific leader in skincare, dedicated to developing and commercializing products for common and underserved skin conditions. It was founded to develop prescription products. Its lead asset, XYNGARI (DMT310), was studied for moderate-to-severe acne, and in March 2025 the company reported statistically significant results from its Phase 3 STAR-1 trial across all three co-primary endpoints at weeks 4, 8 and 12 compared with placebo. In September 2025 management, with its board, chose a strategic shift to developing and distributing direct-to-consumer and business-to-business skincare products backed by science. Its hero ingredient is Spongilla lacustris, a freshwater sponge processed into a powder used in its Bioneedle. The company plans to launch its first cosmetic product in the middle of 2026, with a first over-the-counter acne product to follow shortly after. The planned OTC acne system pairs a weekly Bioneedle treatment with a daily salicylic acid wipe. The company also sees a market for its technology in intradermal delivery of botulinum toxin for aesthetic conditions. The text notes that there are over 50 million acne patients in the U.S.
| Product or program | What it is | Stage |
|---|---|---|
| Bioneedle skin renewal treatment | Once-weekly skin renewal kit using 100% Spongilla lacustris powder | Cosmetic product launch planned for the middle of 2026 |
| OTC topical acne system | Weekly Bioneedle treatment used with a daily salicylic acid wipe for acne | OTC product to follow the cosmetic launch |
| XYNGARI (DMT310) | Former prescription candidate for moderate-to-severe acne | Phase 3 results statistically significant (March 2025); prescription development deprioritized |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.9 million | $8.2 million |
| Net income (loss) | -$7.6 million | -$12.3 million |
| Cash from operations | -$7.8 million | -$11.2 million |
| Cash and equivalents | $7.5 million | $3.2 million |
Our latest story on this, dated May 16, 2025: "Dermata regains Nasdaq stockholders' equity compliance but gets bid price delisting notice". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 17, 2026: "Dermata agrees to $3.4 million private placement with warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 25, 2025: "Dermata Therapeutics gets Nasdaq stockholders' equity deficiency notice, has until May 9, 2025". The story links the filing or release it is based on. Read the story.
Dermata Therapeutics, Inc. trades under the ticker DRMA on NASDAQ.
Dermata Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Dermata Therapeutics, Inc. is 1853816. Its filings are on SEC EDGAR.
4,022,143 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Dermata Therapeutics, Inc. under United States.
Our directory classifies Dermata Therapeutics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Dermata Therapeutics, Inc. is US2498455045.
aibio.space lists Dermata Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Dermata Therapeutics, Inc. describes itself as a scientific leader in skincare, dedicated to developing and commercializing products for common and underserved skin conditions. It was founded to develop prescription products.
Bioneedle skin renewal treatment: Once-weekly skin renewal kit using 100% Spongilla lacustris powder Stage: Cosmetic product launch planned for the middle of 2026.
OTC topical acne system: Weekly Bioneedle treatment used with a daily salicylic acid wipe for acne Stage: OTC product to follow the cosmetic launch.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio